U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H22N2O
Molecular Weight 234.3373
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LIDOCAINE

SMILES

CCN(CC)CC(=O)NC1=C(C)C=CC=C1C

InChI

InChIKey=NNJVILVZKWQKPM-UHFFFAOYSA-N
InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)

HIDE SMILES / InChI

Molecular Formula C14H22N2O
Molecular Weight 234.3373
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Lidocaine is a local anesthetic and cardiac depressant used to numb tissue in a specific area and for management of cardiac arrhythmias, particularly those of ventricular origins, such as occur with acute myocardial infarction. Lidocaine alters signal conduction in neurons by blocking the fast voltage-gated Na+ channels in the neuronal cell membrane responsible for signal propagation. With sufficient blockage, the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain, but by stopping them before they begin. Careful titration allows for a high degree of selectivity in the blockage of sensory neurons, whereas higher concentrations also affect other modalities of neuron signaling. Lidocaine exerts an antiarrhythmic effect by increasing the electrical stimulation threshold of the ventricle during diastole. In usual therapeutic doses, lidocaine hydrochloride produces no change in myocardial contractility, in systemic arterial pressure, or an absolute refractory period. The efficacy profile of lidocaine as a local anesthetic is characterized by a rapid onset of action and intermediate duration of efficacy. Therefore, lidocaine is suitable for infiltration, block, and surface anesthesia. Longer-acting substances such as bupivacaine are sometimes given preference for spinal and epidural anesthesias; lidocaine, though, has the advantage of a rapid onset of action. Lidocaine is also the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias (for acute myocardial infarction, digoxin poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated. Lidocaine should be given for this indication after defibrillation, CPR, and vasopressors have been initiated. A routine preventative dose is no longer recommended after a myocardial infarction as the overall benefit is not convincing. Inhaled lidocaine can be used as a cough suppressor acting peripherally to reduce the cough reflex. This application can be implemented as a safety and comfort measure for patients who have to be intubated, as it reduces the incidence of coughing and any tracheal damage it might cause when emerging from anesthesia. Adverse drug reactions (ADRs) are rare when lidocaine is used as a local anesthetic and is administered correctly. Most ADRs associated with lidocaine for anesthesia relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, and allergic reactions only rarely occur. Systemic exposure to excessive quantities of lidocaine mainly result in a central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations.

Originator

Sources: Arkiv foer Kemi, Mineralogi och Geologi (1946), A22, (No. 18), 30 pp.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
XYLOCAINE

Approved Use

INDICATIONS & USAGE Lidocaine Hydrochloride Oral Topical Solution USP, 2% (Viscous) is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.

Launch Date

1951
Primary
VIAFLEX

Approved Use

Indications and Usage Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of (1) ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and (2) life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction.

Launch Date

1984
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
212 ng/mL
84 mg 1 times / day steady-state, topical
dose: 84 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
LIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
231 ng/mL
84 mg 2 times / day steady-state, topical
dose: 84 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
LIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4100 ng × h/mL
84 mg 1 times / day steady-state, topical
dose: 84 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
LIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4704 ng × h/mL
84 mg 2 times / day steady-state, topical
dose: 84 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
LIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.81 h
84 mg 1 times / day steady-state, topical
dose: 84 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
LIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.94 h
84 mg 2 times / day steady-state, topical
dose: 84 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
LIDOCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg 1 times / day steady, intravenous
Dose: 2 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 17 - 66 years
n = 68
Health Status: unhealthy
Condition: chronic daily headache and chronic cluster headache
Age Group: 17 - 66 years
Sex: M+F
Population Size: 68
Sources:
Other AEs: Nausea and vomiting, Hallucinations...
Other AEs:
Nausea and vomiting (1%)
Hallucinations (8 patients)
Tachycardia (4 patients)
Tremor (3 patients)
Hypotension (2 patients)
Light-headed (1 patient)
Phlebitis (1 patient)
Hypertension (1 patient)
Sources:
800 mg single, intravenous
Overdose
Dose: 800 mg
Route: intravenous
Route: single
Dose: 800 mg
Sources:
unhealthy, 57 years
n = 1
Health Status: unhealthy
Condition: hypertensive, severe precordial pain
Age Group: 57 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Death...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 1.6%)
Sources:
700 mg 1 times / day steady, transdermal
Recommended
Dose: 700 mg, 1 times / day
Route: transdermal
Route: steady
Dose: 700 mg, 1 times / day
Sources:
unhealthy, adult
n = 404
Health Status: unhealthy
Condition: Neuropathic pain
Age Group: adult
Sex: unknown
Population Size: 404
Sources:
5 % 1 times / day steady, transdermal
Dose: 5 %, 1 times / day
Route: transdermal
Route: steady
Dose: 5 %, 1 times / day
Sources:
unhealthy, adult
n = 300
Health Status: unhealthy
Condition: post-herpetic neuralgia and diabetic polyneuropathy
Age Group: adult
Sex: M+F
Population Size: 300
Sources:
Disc. AE: Headache, Application site irritation...
AEs leading to
discontinuation/dose reduction:
Headache (2 patients)
Application site irritation (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypertension 1 patient
2 mg 1 times / day steady, intravenous
Dose: 2 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 17 - 66 years
n = 68
Health Status: unhealthy
Condition: chronic daily headache and chronic cluster headache
Age Group: 17 - 66 years
Sex: M+F
Population Size: 68
Sources:
Light-headed 1 patient
2 mg 1 times / day steady, intravenous
Dose: 2 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 17 - 66 years
n = 68
Health Status: unhealthy
Condition: chronic daily headache and chronic cluster headache
Age Group: 17 - 66 years
Sex: M+F
Population Size: 68
Sources:
Phlebitis 1 patient
2 mg 1 times / day steady, intravenous
Dose: 2 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 17 - 66 years
n = 68
Health Status: unhealthy
Condition: chronic daily headache and chronic cluster headache
Age Group: 17 - 66 years
Sex: M+F
Population Size: 68
Sources:
Nausea and vomiting 1%
2 mg 1 times / day steady, intravenous
Dose: 2 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 17 - 66 years
n = 68
Health Status: unhealthy
Condition: chronic daily headache and chronic cluster headache
Age Group: 17 - 66 years
Sex: M+F
Population Size: 68
Sources:
Hypotension 2 patients
2 mg 1 times / day steady, intravenous
Dose: 2 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 17 - 66 years
n = 68
Health Status: unhealthy
Condition: chronic daily headache and chronic cluster headache
Age Group: 17 - 66 years
Sex: M+F
Population Size: 68
Sources:
Tremor 3 patients
2 mg 1 times / day steady, intravenous
Dose: 2 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 17 - 66 years
n = 68
Health Status: unhealthy
Condition: chronic daily headache and chronic cluster headache
Age Group: 17 - 66 years
Sex: M+F
Population Size: 68
Sources:
Tachycardia 4 patients
2 mg 1 times / day steady, intravenous
Dose: 2 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 17 - 66 years
n = 68
Health Status: unhealthy
Condition: chronic daily headache and chronic cluster headache
Age Group: 17 - 66 years
Sex: M+F
Population Size: 68
Sources:
Hallucinations 8 patients
2 mg 1 times / day steady, intravenous
Dose: 2 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 17 - 66 years
n = 68
Health Status: unhealthy
Condition: chronic daily headache and chronic cluster headache
Age Group: 17 - 66 years
Sex: M+F
Population Size: 68
Sources:
Death grade 5, 1.6%
Disc. AE
800 mg single, intravenous
Overdose
Dose: 800 mg
Route: intravenous
Route: single
Dose: 800 mg
Sources:
unhealthy, 57 years
n = 1
Health Status: unhealthy
Condition: hypertensive, severe precordial pain
Age Group: 57 years
Sex: M
Population Size: 1
Sources:
Application site irritation 2 patients
Disc. AE
5 % 1 times / day steady, transdermal
Dose: 5 %, 1 times / day
Route: transdermal
Route: steady
Dose: 5 %, 1 times / day
Sources:
unhealthy, adult
n = 300
Health Status: unhealthy
Condition: post-herpetic neuralgia and diabetic polyneuropathy
Age Group: adult
Sex: M+F
Population Size: 300
Sources:
Headache 2 patients
Disc. AE
5 % 1 times / day steady, transdermal
Dose: 5 %, 1 times / day
Route: transdermal
Route: steady
Dose: 5 %, 1 times / day
Sources:
unhealthy, adult
n = 300
Health Status: unhealthy
Condition: post-herpetic neuralgia and diabetic polyneuropathy
Age Group: adult
Sex: M+F
Population Size: 300
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
yes
yes (co-administration study)
Comment: CYP1A2 is the enzyme principally responsible for the metabolic disposition of lidocaine in subjects with normal liver function.
Page: -
yes
yes (co-administration study)
Comment: Itraconazole and erythromycin had virtually no effect on the pharmacokinetics of intravenous lidocaine, but erythromycin slightly prolonged the elimination half-life (t½) of lidocaine (Study I). When lidocaine was taken orally, both erythromycin and itraconazole increased the peak concentration (Cmax) and the area under the concentration-time curve (AUC) of lidocaine by 40-70% (Study II).
Page: -
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Horner's syndrome due to epidural analgesia.
1998 Dec
Transient neurological symptoms after spinal anaesthesia with hyperbaric 5% lidocaine or general anaesthesia.
1999 Apr
Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.
1999 Apr
Iontophoretically applied lidocaine reduces pain on propofol injection.
1999 Mar
[Lidocaine induced seizure following topical application of local anesthetics: case report].
1999 May
Potentiation of narcosis after intravenous lidocaine in a patient given spinal opioids.
1999 Sep
Vestibular schwannoma surgery and headache.
2000
Effects of anticonvulsants on local anaesthetic-induced neurotoxicity in rats.
2000 Feb
Low-dose lidocaine reduces secondary hyperalgesia by a central mode of action.
2000 Mar
TASK-3, a new member of the tandem pore K(+) channel family.
2000 Mar 31
A decrease in seizure susceptibility to lidocaine in kindled epileptic rats.
2000 May
Lidocaine-sensitive atrial tachycardia: lidocaine-sensitive, rate-related, repetitive atrial tachycardia: a new arrhythmogenic syndrome.
2000 Nov 1
Peripheral lidocaine but not ketamine inhibits capsaicin-induced hyperalgesia in humans.
2000 Oct
The effect of systemic lidocaine on pain and secondary hyperalgesia associated with the heat/capsaicin sensitization model in healthy volunteers.
2000 Oct
Computerised advice on drug dosage to improve prescribing practice.
2001
Pain management for neonatal circumcision.
2001
[Comment on the article "Use of EMLA cream and ropivacaine indacryocystorhinostomy with locoregional anesthesia and sedation"].
2001 Apr
The efficacy of topical anaesthesia in flexible nasendoscopy: a double-blind randomised controlled trial.
2001 Feb
Articaine hydrochloride: a study of the safety of a new amide local anesthetic.
2001 Feb
Influence of patient posture on oxygen saturation during fibre-optic bronchoscopy.
2001 Jan
Cardiac resuscitation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, and ropivacaine in anesthetized dogs.
2001 Jan
Clonidine in preterm-infant caudal anesthesia may be responsible for postoperative apnea.
2001 Jan-Feb
LET versus EMLA for pretreating lacerations: a randomized trial.
2001 Mar
Penile lymphoscintigraphy for sentinel node identification.
2001 May
Emla versus ice as a topical anesthetic.
2001 May
Inclusion of lignocaine base into a polar lipid formulation--in vitro release, duration of peripheral nerve block and arterial blood concentrations in the rat.
2001 May
Evaluation of pain management interventions for neonatal circumcision pain.
2001 May-Jun
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/08816s032lbl.pdf
Therapy of ventricular arrhythmias is often initiated with a single IV bolus of 1.0 to 1.5 mg/kg at a rate of 25 to 50 mg/min. of lidocaine hydrochloride injection. Following acute treatment by bolus in patients in whom arrhythmias tend to recur and who are incapable of receiving oral antiarrhythmic agents, intravenous infusion of Lidocaine Hydrochloride and 5% Dextrose Injection, USP is administered continuously at the rate of 1 to 4 mg/min (0.020 to 0.050 mg/kg/min in the average 70 kg adult). The 0.4% solution (4 mg/mL) can be given at a rate of 15 to 60 mL/hr (0.25 to 1 mL/min). The 0.8% solution (8 mg/mL) can be given at a rate of 7.5 to 30 mL/hr (0.12 to 0.5 mL/min). Precise dosage regimen is determined by patient characteristics and response.
Route of Administration: Other
Cells were prepared by dissociation from T175 cell culture flasks using trypsineEDTA (0.05%), cells were kept in serum free media in the cell hotel on board the QPatch HT. These cells were sampled, washed and re-suspended in extracellular recording solution by the QPatch HT immediately before application to well site on the chip. Once in whole-cell configuration, vehicle (0.1% DMSO v/v) was applied to the cells to achieve a stable control recording (4-min total). This was followed by application of test concentrations as a single bolus addition (4-min incubation per test concentration). Lidocaine were prepared in extracellular recording solution from a 10mM(100% DMSO) stock to yield a final 10 mkM(0.1% DMSO) test concentration from which subsequent serial dilutions in extracellular solution were performed (0.3-10 mkM). Voltage protocols for the sodium channels being screened were designed to reflect the high-frequency, pathophysiological state of the channels that may be therapeutic targets (Nav1.3, Nav1.4 and Nav1.7), and the lowfrequency, physiological state of the safety target (Nav1.5). Currents were elicited from NaV1.3, NaV1.4 and NaV1.7 cell lines using a standard two-pulse voltage protocol. From a holding potential of -100 mV, a 20 ms activating step to -20 mV was applied to assess the effect of compounds on resting (closed) state block. The second activating pulse was applied following a 5-s pre-pulse to half inactivation potential (variable depending on the sodium channel studied, -65 to -75 mV) to assess block on the openinactivated state of the channel. This protocol was applied at a sweep interval of 0.067 Hz throughout the duration of the experiment.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:22:36 GMT 2023
Edited
by admin
on Fri Dec 15 15:22:36 GMT 2023
Record UNII
98PI200987
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LIDOCAINE
EP   GREEN BOOK   HSDB   INCI   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN   INCI  
Official Name English
LIDOCAINE [HSDB]
Common Name English
lidocaine [INN]
Common Name English
2-(DIETHYLAMINO)-N-(2,6-DIMETHYLPHENYL)ACETAMIDE
Systematic Name English
EMLA COMPONENT LIDOCAINE
Common Name English
ZTLIDO
Brand Name English
LIDOCAINE COMPONENT OF ORAQIX
Common Name English
LANABIOTIC COMPONENT LIDOCAINE
Common Name English
LIDOCAINE [WHO-IP]
Common Name English
LIGNOCAINE
Common Name English
LIDOCAINE COMPONENT OF ROCEPHIN KIT
Common Name English
LIDOCAINE COMPONENT OF EMLA
Common Name English
LIDOCAINE [EP MONOGRAPH]
Common Name English
LIDOCAINE COMPONENT OF SYNERA
Common Name English
XYLESTESIN
Common Name English
2-(DIETHYLAMINO)-2',6'-ACETOXYLIDIDE
Common Name English
FORTACIN COMPONENT LIDOCAINE
Brand Name English
DIETHYLAMINO-2,6-DIMETHYLACETANILIDE
Common Name English
LIDOCAINE [INCI]
Common Name English
LIDOCAINE [USP-RS]
Common Name English
LIDOCAINE [MI]
Common Name English
LIDOCAINE [VANDF]
Common Name English
DENTIPATCH
Brand Name English
LIDOCAINE COMPONENT OF LANABIOTIC
Common Name English
LIDOCAINE [USP MONOGRAPH]
Common Name English
Lidocaine [WHO-DD]
Common Name English
LIDOCAINE [MART.]
Common Name English
ORAQIX COMPONENT LIDOCAINE
Common Name English
LIDOCAINE [ORANGE BOOK]
Common Name English
SYNERA COMPONENT LIDOCAINE
Common Name English
ROCEPHIN KIT COMPONENT LIDOCAINE
Common Name English
ALGRX 3268
Code English
LIDOCAIN COMPONENT OF FORTACINE
Brand Name English
LIDOCAINE [JAN]
Common Name English
LIDOCAINE [GREEN BOOK]
Common Name English
LIDODERM
Brand Name English
XYLOCAINE
Common Name English
NSC-40030
Code English
ALPHACAINE
Brand Name English
ALGRX-3268
Code English
ACETAMIDE, 2-(DIETHYLAMINO)-N-(2,6-DIMETHYLPHENYL)-
Systematic Name English
2-DIETHYLAMINO-2',6'-ACETOXYLIDIDE
Common Name English
SOLARCAINE
Common Name English
LIDOCAINUM [WHO-IP LATIN]
Common Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 1.2 (LID/EPI)
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 1.2
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
CFR 21 CFR 348.10
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
CFR 21 CFR 522.810
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
NDF-RT N0000175976
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
NCI_THESAURUS C245
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-ATC C01BB01
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-ATC N01BB02
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-ATC C05AD01
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-VATC QD04AB01
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
CFR 21 CFR 862.3555
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-VATC QC01BB01
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-ATC N01BB52
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-VATC QS02DA01
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
CFR 21 CFR 346.10
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
NDF-RT N0000007681
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
FDA ORPHAN DRUG 92395
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-ATC D04AB01
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-ATC S01HA07
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-VATC QN01BB02
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-VATC QD04AB51
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-VATC QS01HA07
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-ATC R02AD02
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
NDF-RT N0000175426
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
CFR 21 CFR 522.1662B
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-VATC QN01BB52
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
NDF-RT N0000175682
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
NCI_THESAURUS C93038
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 12.2
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
EMA ASSESSMENT REPORTS FORTACIN (AUTHORIZED: SEXUAL DYSFUNCTION, PHYSIOLOGICAL)
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-ATC S02DA01
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-VATC QC05AD01
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
WHO-VATC QR02AD02
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
Code System Code Type Description
HSDB
3350
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
ECHA (EC/EINECS)
205-302-8
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
EPA CompTox
DTXSID1045166
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
NCI_THESAURUS
C614
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
MERCK INDEX
m6805
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY Merck Index
PUBCHEM
3676
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
INN
4202
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
RXCUI
6387
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY RxNorm
WHO INTERNATIONAL PHARMACOPEIA
LIDOCAINE
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY Description: A white or slightly yellow, crystalline powder; odour, characteristic. Solubility: Practically insoluble in water; very soluble in ethanol (~750 g/l) TS; freely soluble in benzene R and ether R. Category: Local anaesthetic. Storage: Lidocaine should be kept in a tightly closed container, protected from light. Additional information: Lidocaine causes local numbness after being placed on the tongue. Definition: Lidocaine contains not less than 99.0% and not more than 101.0% of C14H22N2O, calculated with reference to the dried substance.
DRUG CENTRAL
1579
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
DRUG BANK
DB00281
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
CAS
91484-71-8
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
SUPERSEDED
SMS_ID
100000091713
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
ChEMBL
CHEMBL79
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
IUPHAR
2623
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
FDA UNII
98PI200987
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
LACTMED
Lidocaine
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
NSC
40030
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
RS_ITEM_NUM
1366002
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
DAILYMED
98PI200987
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
EVMPD
SUB08507MIG
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
MESH
D008012
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
WIKIPEDIA
LIDOCAINE
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
CHEBI
6456
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
CAS
137-58-6
Created by admin on Fri Dec 15 15:22:36 GMT 2023 , Edited by admin on Fri Dec 15 15:22:36 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
METABOLIC ENZYME -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
BASIS OF STRENGTH->SUBSTANCE
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
METABOLITE LESS ACTIVE -> PARENT
PLASMA
METABOLITE INACTIVE -> PARENT
has unknown pharmacologic activity but is carcinogenic in rats (http://srsid.fda.gov:9618/ePS/SubstanceRelationship.do?substanceMode=update&calledFrom=viewUpdateIngredient&RELATIONSHIP_ID=128538&SUBSTANCE_ID=1422&BDNUM=0021807AA).
PLASMA
METABOLITE TOXIC -> PARENT
Adversely affected mental performance and caused headaches in man.
METABOLITE LESS ACTIVE -> PARENT
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE INACTIVE -> PARENT
major excreted metabolite.
MAJOR
URINE
Related Record Type Details
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC Crosses blood-brain barrier